Please select the option that best describes you:
Would repeat MMR/HER-2 or NGS testing be beneficial during progression of gastric cancer in patients who have already received first line chemotherapy?
Patients with gastric cancer can acquire new targetable mutations on progression. This could aid in additional treatment options in this group which tend to have poorer outcomes.
Answer from: Medical Oncologist at Academic Institution
There are really no good data one way or another, as far as I know, so any views expressed here are purely anecdotal and personal opinions.As a group and speaking for myself, I rarely repeat NGS. The bigger picture is that we identify actionable alterations in esophagogastric cancer no more than 5% ...
Sign in or Register to read more